-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Source: Instant Medicine
On March 12, the website of China National Medical Products Administration (NMPA) showed that Huahao Zhongtian's Class 1 new drug Utidelon obtained the drug approval number.
.
Data in 2020 show that the number of new breast cancers reached 2.
Utidrolone is a genetically engineered epothilone (epothilones) derivative.
In addition to being used for chemotherapy of advanced breast cancer, Utidelone has also shown anti-tumor activity against common tumors such as lung cancer, liver cancer, bowel cancer and prostate cancer in previous studies, and is resistant to paclitaxel and many other chemotherapeutic drugs.
It is hoped that this drug can bring new treatment options to breast cancer patients, and it is also expected that it can help improve the lives of more patients in the future.
Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.
Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.
Reference materials:
[1] On March 12, 2021, the drug approval document pending information is released.
[1] On March 12, 2021, the drug approval document pending information is released.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.